← Leaderboards
Bettina Fries
Yeshiva University
$11,552,965
Attributed
$11,552,965
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,552,965 · 8
VA$0 · 1
By mechanism
R01$6,776,936 · 2
U54$2,606,787 · 1
R21$1,120,583 · 3
R56$555,099 · 1
K08$493,560 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Yeshiva University
Same institution · by research overlap
- Liise-Anne Pirofski$20,784,118
- Ekaterina Dadachova$3,442,959
- Herbert Bernard Tanowitz$11,025,489
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenIn VivoResistanceBasePhenotypeMutantIn VitroCryptococcus NeoformansAffectVirulenceProteinsVariantMacrophageAnimal ModelLeadApplications GrantsImmune ResponseExhibitsPolysaccharidesCellsLaboratoriesChronicMortality
Grant awards (36)
Host-Pathogen Dynamics in Microglia during C. neoformans and HIV Co-infection$232,073
R21 · FY2025 · AI · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2025 · VA · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2024 · VA · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$555,099
R56 · FY2023 · AI · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2022 · VA · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$618,336
R01 · FY2021 · AI · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2021 · VA · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$618,336
R01 · FY2020 · AI · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2020 · VA · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$618,335
R01 · FY2019 · AI · contact PI
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258$0
I01 · FY2019 · VA · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$617,819
R01 · FY2018 · AI · contact PI
Investigation on Replicative aging in Cryptococcus neoformans populations$687,784
R01 · FY2017 · AI · contact PI
Development of antibodies to capsule of carbapenem resistant Klebsiella pneumonia$197,500
R21 · FY2016 · AI · contact PI
Development of antibodies to capsule of carbapenem resistant Klebsiella pneumonia$237,000
R21 · FY2015 · AI · contact PI
Host Response to Phenotypic Switch Variant of C. Neoformans$371,300
R01 · FY2014 · AI · contact PI
Host Response to Phenotypic Switch Variants of C. Neoformans$43,700
R01 · FY2014 · AI · contact PI
Optimization of mAbs to staphylococcal enterotoxin B for treatment$440,980
U54 · FY2013 · AI · contact PI
Host Response to Phenotypic Switch Variants of C. Neoformans$390,100
R01 · FY2013 · AI · contact PI
Optimization of mAbs to staphylococcal enterotoxin B for treatment$440,345
U54 · FY2012 · AI · contact PI
Host Response to Phenotypic Switch Variants of C. Neoformans$415,000
R01 · FY2012 · AI · contact PI
Optimization of mAbs to staphylococcal enterotoxin B for treatment$574,345
U54 · FY2011 · AI · contact PI
Host Response to Phenotypic Switch Variants of C. Neoformans$415,000
R01 · FY2011 · AI · contact PI
Consequences of replicative aging in Cryptococcus neoformans$246,510
R21 · FY2011 · AI · contact PI
Optimization of mAbs to staphylococcal enterotoxin B for treatment$621,601
U54 · FY2010 · AI · contact PI
Consequences of replicative aging in Cryptococcus neoformans$207,500
R21 · FY2010 · AI · contact PI
Optimization of mAbs to staphylococcal enterotoxin B for treatment$529,516
U54 · FY2009 · AI · contact PI
response to phenotypic switch variants to C. neoformans$404,708
R01 · FY2008 · AI · contact PI
response to phenotypic switch variants to C. neoformans$412,547
R01 · FY2007 · AI · contact PI
response to phenotypic switch variants to C. neoformans$412,471
R01 · FY2006 · AI · contact PI
response to phenotypic switch variants to C. neoformans$375,750
R01 · FY2005 · AI
response to phenotypic switch variants to C. neoformans$375,750
R01 · FY2004 · AI
MOLECULAR BASIS OF PHENOTYPIC SWITCHING IN 24067 MUTANT$126,090
K08 · FY2003 · AI
MOLECULAR BASIS OF PHENOTYPIC SWITCHING IN 24067 MUTANT$126,090
K08 · FY2002 · AI
MOLECULAR BASIS OF PHENOTYPIC SWITCHING IN 24067 MUTANT$126,090
K08 · FY2001 · AI
MOLECULAR BASIS OF PHENOTYPIC SWITCHING IN 24067 MUTANT$115,290
K08 · FY2000 · AI